As this happened, Piper Sandler downgraded its Achilles Therapeutics Plc ADR [ACHL] rating to a Neutral from a an Overweight in a research note published on April 05, 2024; the price target was decreased to $2 from $8. A number of analysts have revised their coverage, including Piper Sandler’s analysts, who began to cover the stock in late April with a ‘”an Overweight”‘ rating. Oppenheimer began covering ACHL with “an Outperform” recommendation on April 26, 2021. JP Morgan started covering the stock on April 26, 2021. It rated ACHL as “an Underweight”.
Price Performance Review of ACHL
On Tuesday, Achilles Therapeutics Plc ADR [NASDAQ:ACHL] saw its stock jump 21.43% to $1.36. Over the last five days, the stock has gained 19.82%. Achilles Therapeutics Plc ADR shares have risen nearly 19.30% since the year began. Nevertheless, the stocks have risen 36.00% over the past one year. While a 52-week high of $1.76 was reached on 02/04/25, a 52-week low of $0.63 was recorded on 02/03/25. SMA at 50 days reached $1.1002, while 200 days put it at $0.9305.
Levels Of Support And Resistance For ACHL Stock
The 24-hour chart illustrates a support level at 1.3367, which if violated will result in even more drops to 1.3133. On the upside, there is a resistance level at 1.3967. A further resistance level may holdings at 1.4333. The Relative Strength Index (RSI) on the 14-day chart is 79.36, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.0474, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 15.87%. Stochastics %K at 51.65% indicates the stock is a holding.
How much short interest is there in Achilles Therapeutics Plc ADR?
A steep rise in short interest was recorded in Achilles Therapeutics Plc ADR stocks on 2024-10-31, dropping by -0.2 million shares to a total of 0.16 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-30 was 0.36 million shares. There was a decline of -124.88%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on April 26, 2021 when Chardan Capital Markets began covering the stock and recommended ‘”a Buy”‘ rating along with a $27 price target.
